USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Merrifield Research
Address:
2723-B Merrilee Drive
Fairfax, VA 22031
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $299,884.00 6
SBIR Phase II $999,719.00 2

Award List:

SERUM ERYTHROPOIETIN BIOASSAY USING A NEW CELL LINE

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,942.00
Agency:
HHS
Principal Investigator:
Hankins, David W , Principal Investigator
Abstract:
N/a

INDENTIFICATION OF HUMAN F CELL GROWTH FACTOR

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Davis W Hankins
Abstract:
N/a

SERUM ERYTHROPOIETIN BIOASSAY USING A NEW CELL LINE

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$499,719.00
Agency:
HHS
Principal Investigator:
Hankins, David W , Principal Investigator
Abstract:
We plan to exploit the isolation of a cell line from erythroleukemic murine tumors which is highly sensitive line from erythroleukemic murine tumors which is highly sensitive to erythropoietin. we will utilize this line to develop a sensitive and specific bioassay for erythropoietin in human serum.… More

INDENTIFICATION OF HUMAN F CELL GROWTH FACTOR

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Davis W Hankins
Abstract:
Fetal hemoglobin can greatly reduce the symptons of hemoglobin disorders such as sickle cell amemia and b-thalassemia diseases which affect millions of people worldwide. cytotoxic agents are currently being used to attempt to switch the adult program of hemoglobin syntehsis to fetal hemoglobin in… More

Anti-Hormonal Approach to Leukemia Cytokine Receptor

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
David W. Hankins
Abstract:
Approximately half of the individuals diagnosed with cancer will die of the disease even if the receive the best therapies that modern medicine has to offer. In addition, even with current therapies, including surgery, radiation, and chemotherapy induced remission, the side effects are ravaging and… More

Anti-Hormonal Approach to Leukemia¿Radioactive Ligand

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
David W. Hankins
Abstract:
Approximately half of the individuals diagnosed with cancer will die of the disease even if they receive the best therapies that modern medicine has to offer. In addition, even with current therapies, including surgery, radiation, and chemotherapy induced remission, the side effects are ravaging and… More

Blood Cytokines for In Utero Bone Marrow Transplantation

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,942.00
Agency:
HHS
Principal Investigator:
David W. Hankins
Abstract:
Human bone marrow can be transplanted into sheep fetuses when administered in utero. Upon birth of the sheep, the human hematopoietic stemcells produce differentiated human blood cells in the lymphoid erythroid and myeloid lineages for at least two years. Thus, the sheep/human chimera is an… More

Clinical Hemopoietin Assay By Receptor-ligand Binding

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
David W. Hankins
Abstract:
Current assays from clinical quanititation of cytokines such as the interleukins, colony stimulating factors and erythropoietin (Epo) are based on monocional or polycional antibody recognition of the hormone on the form RIA's or ELISAs. This approach requires much time and effort to develop… More